Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
73 hedge funds and large institutions have $179M invested in Viracta Therapeutics, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 27 increasing their positions, 21 reducing their positions, and 15 closing their positions.
11,700% more call options, than puts
Call options by funds: $236K | Put options by funds: $2K
29% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 21
1% less capital invested
Capital invested by funds: $180M → $179M (-$1.73M)
3% less funds holding
Funds holding: 75 → 73 (-2)
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.2M |
| 2 |
DCM
Decade Capital Management
New York
|
+$2.79M |
| 3 |
CI
Cowen Inc
New York
|
+$2.3M |
| 4 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
+$2.14M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$5.84M |
| 2 |
Millennium Management
New York
|
-$4.08M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.51M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$1.43M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$939K |
VIRX Hedge Fund Activity: Q3 2013 in Review
73 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2013, worth a combined $179M — down 0.96% from $180M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of VIRX and 13 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 27 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $10.2M. The largest seller was Bank of New York Mellon, cutting an estimated $5.84M.
- 73 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2013, down from 75 in Q2 2013.
- Funds reported $179M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2013, down 0.96% quarter-over-quarter.
- 13 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2013 and 15 closed out, a net change of -2 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2013 was T. Rowe Price Associates, an estimated $10.2M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2013 was Bank of New York Mellon, an estimated $5.84M sold.
Based on aggregated 13F filings for Q3 2013.